A good candidate for TAVR (transcatheter aortic valve replacement) is someone with severe aortic stenosis whose valve has narrowed enough to cause symptoms or measurable heart strain, and whose anatomy allows a replacement valve to be delivered through a blood vessel rather than through open-chest surgery. The procedure was originally reserved for patients too sick for traditional surgery, but current guidelines now support it across a wide range of surgical risk levels, with age and life expectancy playing a central role in the decision.
Severe Aortic Stenosis Is the Starting Point
TAVR addresses one specific problem: a severely narrowed aortic valve that restricts blood flow out of the heart. Not all aortic stenosis qualifies. The valve must meet specific thresholds on an echocardiogram: a mean pressure gradient above 40 mmHg, blood velocity across the valve greater than 4.0 m/s, and a valve opening area smaller than 0.8 square centimeters. In practical terms, a healthy aortic valve opens to about 3 to 4 square centimeters, so a valve below 0.8 is dramatically restricted.
Most candidates have symptoms like shortness of breath during activity, chest tightness, fainting or near-fainting, or unusual fatigue. Some patients without obvious symptoms still qualify if exercise testing reveals abnormal heart responses, such as a drop in blood pressure or new symptoms under exertion that they hadn’t noticed in daily life.
How Age and Surgical Risk Shape the Decision
Current ACC/AHA guidelines use age brackets and life expectancy to guide whether TAVR or traditional open-heart surgery (SAVR) is the better option. For patients over 80, or those with a life expectancy under 10 years, or those facing high or prohibitive surgical risk, TAVR is the recommended approach, provided post-procedure survival is expected to exceed 12 months with reasonable quality of life.
For patients between 65 and 80, the choice between TAVR and open surgery depends on anatomy, individual risk factors, and a shared conversation between the patient and their care team. Patients under 65 with a life expectancy over 20 years are generally steered toward open surgery. The reason comes down to valve durability: a TAVR valve is biological tissue mounted on a metal frame, and its long-term performance in younger patients is still being studied.
Surgical risk is formally scored using a predictive model called the STS PROM, which estimates the chance of dying from open-heart surgery based on age, kidney function, lung disease, prior surgeries, and other factors. A score below 4% is considered low risk. Patients at intermediate, high, or prohibitive risk levels have been shown in major clinical trials to do as well with TAVR as with surgery, or better.
What the 10-Year Durability Data Shows
One of the biggest questions for any TAVR candidate is how long the new valve will last. A study tracking patients with a self-expanding TAVR valve found that 96.1% were free from valve failure at 10 years using actual (real-world) measurement. The actuarial estimate, which projects what would happen if all patients survived long enough to be tracked, was 78.8% freedom from failure at 10 years.
The catch is that this study followed patients mostly in their 80s with significant other health conditions. Almost 90% had died of other causes by the 10-year mark, meaning the valves outlasted the patients in most cases. For younger, healthier patients considering TAVR, the question of whether a TAVR valve will hold up for 15 or 20 years remains open. This is a major reason guidelines still favor open surgery for people under 65 who have decades of life ahead.
Anatomy That Makes TAVR Possible
Even if your disease severity and risk profile point toward TAVR, your anatomy has to cooperate. The procedure most commonly delivers the new valve through the femoral artery in the groin, and that artery needs to be large enough and healthy enough to accommodate the delivery catheter. Average femoral artery diameter in TAVR candidates is about 7.7 mm, and most modern valve systems fit comfortably through vessels of that size. Significant calcification, extreme tortuosity (twisting), or very small vessels can make femoral access unsafe.
The aortic annulus, the ring of tissue where the new valve sits, also has to fall within a specific size range, generally between 18 mm and 29 mm. Too small and the valve won’t seat properly; too large and it can’t form a tight seal, leading to leakage around the edges. The distance between the valve and the openings of the coronary arteries matters too. If the coronary openings sit very close to the annulus, deploying a new valve could block blood flow to the heart muscle itself.
All of this is mapped out before the procedure using a CT scan that creates a detailed 3D picture of the heart, aorta, and leg arteries. If femoral access isn’t feasible, alternative routes through the chest wall, shoulder artery, or directly through the aorta may be options, though femoral access remains the safest and most common approach.
Who Does Not Qualify
Several conditions rule out TAVR entirely. An active infection of the heart valve (endocarditis) must be treated before any valve replacement can be considered. A blood clot in the left ventricle creates an unacceptable risk of stroke during the procedure. Patients with heavy, mobile plaque deposits in the ascending aorta or aortic arch face similar stroke concerns.
A life expectancy under one year from other illnesses, such as advanced cancer or severe organ failure, is an absolute contraindication. The reasoning is straightforward: TAVR carries real procedural risk, and if the patient’s life is limited by something else entirely, the new valve won’t meaningfully improve their time or quality of life. Similarly, if a patient’s symptoms are primarily driven by a different valve problem that requires open surgery anyway, TAVR alone won’t solve the issue.
Relative contraindications, meaning situations that don’t automatically disqualify you but require careful consideration, include untreated blockages in the coronary arteries, very weak heart pump function (ejection fraction below 20%), and hemodynamic instability where blood pressure is difficult to maintain.
Bicuspid Valves: A Gray Area
Most people are born with an aortic valve that has three flaps (leaflets). About 1 to 2% of the population has a bicuspid valve with only two. Bicuspid valves tend to develop stenosis earlier in life, often in the 50s or 60s rather than the 70s or 80s, and their irregular shape can make seating a TAVR valve more challenging.
Bicuspid anatomy was once considered a disqualifying factor for TAVR, but that’s shifted. A registry-based study published in JAMA found no significant difference in 30-day or 1-year death rates between bicuspid and standard three-leaflet TAVR patients, though bicuspid patients did have a higher 30-day stroke risk. TAVR in bicuspid patients is still performed selectively, typically in those who face high surgical risk, and outcomes continue to improve as valve designs evolve and operators gain experience.
The Evaluation Process
TAVR candidacy is never decided by a single doctor. Guidelines require a “heart team” that includes an interventional cardiologist, a cardiac surgeon, and often an imaging specialist and anesthesiologist. This team reviews your echocardiogram results, CT imaging, lung function, kidney health, and overall frailty to determine whether TAVR is the right fit, whether open surgery would serve you better, or whether the risks of any intervention outweigh the benefits.
The evaluation typically includes blood work, a CT scan of the chest, abdomen, and pelvis, an echocardiogram, and sometimes a cardiac catheterization to check for coronary artery disease. Lung function testing and a dental evaluation (to rule out infection sources) are also common. The entire workup can take a few weeks, though some centers complete it faster.
What Recovery Looks Like
One of the reasons TAVR has expanded so rapidly is the recovery. Most patients leave the hospital the same day or the next day. Some stay two days or more depending on complications or other health conditions. Within days, most people return to light daily activities like walking, cooking, and light household tasks. Heavy lifting and strenuous exercise typically need to wait at least a week. Compared to open-heart surgery, which involves splitting the breastbone and usually requires a 5- to 7-day hospital stay followed by weeks of restricted activity, the difference in recovery is dramatic and often the deciding factor for older patients.